Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H22N2O2 |
Molecular Weight | 358.433 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCN1C=C(C(=O)OC2=C3N=CC=CC3=CC=C2)C4=C1C=CC=C4
InChI
InChIKey=ZAVGICCEAOUWFM-UHFFFAOYSA-N
InChI=1S/C23H22N2O2/c1-2-3-6-15-25-16-19(18-11-4-5-12-20(18)25)23(26)27-21-13-7-9-17-10-8-14-24-22(17)21/h4-5,7-14,16H,2-3,6,15H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25921407Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27632803
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25921407
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27632803
PB-22, a recreational “designer drugs”, is a cannabimimetic agent, it is a full agonist of cannabinoid receptors. PB-22 has an EC50 of 5.1 nM for human CB1 receptors, and 37 nM for human CB2 receptors. PB-22 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, suggesting potent cannabinoid-like activity. PB-22 was designated as a Schedule I controlled substance in the United States.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25921407 |
37.0 nM [EC50] | ||
Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25921407 |
5.1 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. | 2015 Aug 19 |
|
Schedules of Controlled Substances: Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA into Schedule I. Final rule. | 2016 Sep 6 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25921407
PB-22 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg intraperitoneally
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25921407
PB-22 revealed agonistic activity at human CB1 or CB2 receptors (CB1 EC50 = 5.1 nM; CB2 EC50 = 37 nM) in AtT20 neuroblastoma cells, stably transfected with human CB1 or CB2 receptors
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
7222
Created by
admin on Sat Dec 16 02:15:03 GMT 2023 , Edited by admin on Sat Dec 16 02:15:03 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-PB-22
Created by
admin on Sat Dec 16 02:15:03 GMT 2023 , Edited by admin on Sat Dec 16 02:15:03 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1400742-17-7
Created by
admin on Sat Dec 16 02:15:03 GMT 2023 , Edited by admin on Sat Dec 16 02:15:03 GMT 2023
|
PRIMARY | |||
|
DTXSID70856177
Created by
admin on Sat Dec 16 02:15:03 GMT 2023 , Edited by admin on Sat Dec 16 02:15:03 GMT 2023
|
PRIMARY | |||
|
QM6J8F29FE
Created by
admin on Sat Dec 16 02:15:03 GMT 2023 , Edited by admin on Sat Dec 16 02:15:03 GMT 2023
|
PRIMARY | |||
|
PB-22
Created by
admin on Sat Dec 16 02:15:03 GMT 2023 , Edited by admin on Sat Dec 16 02:15:03 GMT 2023
|
PRIMARY | |||
|
71604304
Created by
admin on Sat Dec 16 02:15:03 GMT 2023 , Edited by admin on Sat Dec 16 02:15:03 GMT 2023
|
PRIMARY |
ACTIVE MOIETY